NeuroPace reported Q1 2026 results showing continued revenue growth driven by increased adoption of its brain-responsive neurostimulation system for drug-resistant focal epilepsy. The RNS System remains differentiated by its ability to deliver personalized electrical stimulation guided by real-time brain data, enabling durable seizure reduction in a difficult-to-treat patient population. The company targets comprehensive epilepsy centers and community specialists but faces challenges from supply chain vulnerabilities, reimbursement complexities, and regulatory compliance demands. Ongoing label expansion efforts and AI-driven analytics underpin growth potential while commercial execution depends on navigating competitive treatment alternatives and market constraints.